Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.39 |
| ▸ | RXRA | P19793 | 8/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18157605 | 0.92 | PTGS2 (0.39) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL16083580 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL19648306 | 0.89 | PTGS2 (0.36) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL16083370 | 0.89 | PTGS2 (0.36) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL16083583 | 0.89 | NR1H2 (0.39) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL16083455 | 0.88 | NR1H2 (0.37) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL18157694 | 0.86 | PTGS2 (0.39) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL18125847 | 0.85 | PTGS2 (0.40) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL18157541 | 0.85 | PTGS2 (0.39) | NR1H2NR1H3RXRAPTGS2PTGS1 | |
| SCHEMBL18160215 | 0.84 | NR1H2 (0.45) | NR1H2NR1H3RXRAPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834542-B2 | LXR modulators | BRISTO-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | claimed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | claimed |
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | Asteroid Therapeutics (US) | 2024-09-05 | — | — | US | disclosed |
| US-9834542-B2 | LXR modulators | BRISTO-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2014144037-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 5/4885 |
| US-20160304499-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.